Drug Trial Radar · NCT04067336
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Last checked: Nov 21, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
263
Planned (sponsor's estimate)
Start
Sep 12, 2019
Primary completion
Oct 16, 2028
Study completion Oct 16, 2028
Sponsor
- Lead sponsor
- Kura Oncology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 26, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this trial, ziftomenib, a menin-MLL(KMT2A) inhibitor, will be tested in patients for the first time. The trial includes a Main Study and four sub-studies. In the Main Study (including Phase 1a, Phase 1b, and Phase 2 portions), ziftomenib will be evaluated in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has completed enrollment. In Sub-studies 1 and 2, the effects of taking ziftomenib and other common drugs at the same time will be investigated in AML patients. In Sub-study 3, ziftomenib will be evaluated in patients with R/R acute lymphoblastic leukemia (ALL). In Sub-study 4, ziftomenib will be evaluated in patients with R/R AML with certain genetic mutations.
Conditions
- Advanced Malignant Neoplasm
- Acute Myeloid Leukemia
- Mixed Lineage Leukemia
- Mixed Lineage Acute Leukemia
- Acute Leukemia of Ambiguous Lineage
- Mixed Phenotype Acute Leukemia
- Acute Lymphoblastic Leukemia
Interventions
ZiftomenibDrug
Oral administration
MidazolamDrug
Oral administration
ItraconazoleDrug
Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1a: Maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D)Time frame: Dose Limiting Toxicities (DLTs) will be evaluated during the first 28 days (1 cycle)
- Phase 1b: Number of patients who experience Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: During treatment and up to approximately 28 days after treatment discontinuation, or until immediately before the initiation of another anticancer therapy, whichever occurs first.
- Phase 1b: Minimum biologically effective doseTime frame: For at least 12 months following end of treatment
- Phase 1a, 1b, and 2: Evidence of anti-leukemia activityTime frame: For at least 12 months following end of treatment
- Sub-study 1: Time to observed maximum plasma concentration (Tmax) of ziftomenib and midazolamTime frame: Cycle 1 on Days 1 and 15 at predose and postdose
- Sub-study 1: Area under the plasma concentration-time curve from time 0 to time t (AUC0-t) of ziftomenib and midazolamTime frame: Cycle 1 on Days 1 and 15 at predose and postdose
- Sub-study 1: Maximum observed plasma concentration (Cmax) of ziftomenib and midazolamTime frame: Cycle 1 on Days 1 and 15 at predose and postdose
- Sub-study 2: Time to observed maximum plasma concentration (Tmax) of ziftomenib and itraconazoleTime frame: Cycle 1 on Days 1, 15, and 22 at predose and postdose
- Sub-study 2: Area under the plasma concentration-time curve from time 0 to time t (AUC0-t) of ziftomenib and itraconazoleTime frame: Cycle 1 on Days 1, 15, and 22 at predose and postdose
- Sub-study 2: Maximum observed plasma concentration (Cmax) of ziftomenib and itraconazoleTime frame: Cycle 1 on Days 1, 15, and 22 at predose and postdose
- Sub-study 3: Minimum biologically effective dose (MBED) and/or the recommended Phase 2 dose (RP2D)Time frame: During treatment and up to approximately 28 days after treatment discontinuation, or until immediately before the initiation of another anticancer therapy, whichever occurs first
- Sub-study 3: Minimum biologically effective dose (MBED) and/or the recommended Phase 2 dose (RP2D)Time frame: For at least 12 months following end of treatment
- Sub-study 3: Change in Eastern Cooperative Oncology Group (ECOG) statusTime frame: Timeframe: from Baseline to End of Treatment
- Sub-study 3: Time to observed maximum plasma concentration (Tmax) of ziftomenibTime frame: Postdose on Cycle 1 Day 1 and Cycle 2 Day 1. Predose at Cycle 2 onwards
- Sub-study 3: Area under the plasma concentration-time curve from time 0 to time t (AUC0-t) of ziftomenibTime frame: Postdose on Cycle 1 Day 1 and Cycle 2 Day 1. Predose at Cycle 2 onwards
- Sub-study 3: Maximum observed plasma concentration (Cmax) of ziftomenibTime frame: Postdose on Cycle 1 Day 1 and Cycle 2 Day 1. Predose at Cycle 2 onwards.
- Sub-study 4: Complete remission (CR) and complete remission with partial hematologic recovery (CRh)Time frame: For at least 12 months following end of treatment
Locations
43 sites in 7 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona
UCLA Ronald Reagan Medical Center
Los Angeles, California
Mayo Clinic
Jacksonville, Florida
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
University of Michigan Hospitals
Ann Arbor, Michigan
Karmanos Cancer Institute
Detroit, Michigan
Mayo Clinic
Rochester, Minnesota
Hackensack University Medical Center - John Theurer Cancer Center
Hackensack, New Jersey
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Weill Cornell Medical College - NY Presbyterian Hospital
New York, New York
The Mount Sinai Hospital
New York, New York
Duke Cancer Institute
Durham, North Carolina
Oklahoma University Health - Stephenson Cancer Center
Oklahoma City, Oklahoma
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
Harold C. Simmons Comprehensive Cancer Center - UT Southwestern Medical Center
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
Fred Hutchinson Cancer Research Center
Seattle, Washington
AZ Delta - Campus Rumbeke
Roeselare, Belgium
Queen Elizabeth II Health Sciences Centre
Halifax, Nova Scotia, Canada
Hopital Maisonneuve-Rosemont
Montreal, Quebec, Canada
Hopital de l'Enfant-Jesus - Centre Integre en Cancerologie du CHU de Quebec - Universite Laval
Québec, Quebec, Canada
Centre Hospitalier Universitaire de Lille
Lille, France
Centre Hospitalier Universitaire de Nantes
Nantes, France
Hopital Saint Louis
Paris, France
Magendie Hopital Haut-Leveque
Pessac, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
Institut Gustave Roussy
Villejuif, France
University Medicine Greifswald
Greifswald, Germany
Medizinische Hochsschule Hannover
Hanover, Germany
Institute of Hematology and Medical Oncology "L. and A. Seragnoli"
Bologna, Italy
IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Meldola, Italy
UO Ematologia Ospedale di Ravenna
Ravenna, Italy
Institution Fondazione Policlinico Tor Vergata
Roma, Italy
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Universitat de Barcelona
Barcelona, Spain
MD Anderson Cancer Center
Madrid, Spain
Hospital Universitario HM Sanchinarro
Madrid, Spain
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.